JP2003528805A5 - - Google Patents

Download PDF

Info

Publication number
JP2003528805A5
JP2003528805A5 JP2001509208A JP2001509208A JP2003528805A5 JP 2003528805 A5 JP2003528805 A5 JP 2003528805A5 JP 2001509208 A JP2001509208 A JP 2001509208A JP 2001509208 A JP2001509208 A JP 2001509208A JP 2003528805 A5 JP2003528805 A5 JP 2003528805A5
Authority
JP
Japan
Prior art keywords
antibody
medicine
mammal
dose
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001509208A
Other languages
English (en)
Other versions
JP2003528805A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/018776 external-priority patent/WO2001003734A1/en
Publication of JP2003528805A publication Critical patent/JP2003528805A/ja
Publication of JP2003528805A5 publication Critical patent/JP2003528805A5/ja
Withdrawn legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項１】 哺乳動物が悪性腫瘍を羅患していない場合に哺乳動物における異種抗原に対する免疫応答をブロックするための医薬において、ＣＤ２０に結合する治療有効量の抗体を含有してなる医薬。
【請求項２】 哺乳動物がヒトである請求項１に記載の医薬。
【請求項３】 抗体が細胞障害剤とコンジュゲートしていない請求項１に記載の医薬。
【請求項４】 抗体がリツキシマブ(リツキサン(登録商標))を含んでなる請求項１に記載の医薬。
【請求項５】 抗体が細胞障害剤とコンジュゲートしている請求項１に記載の医薬。
【請求項６】 細胞障害剤が放射活性化合物である請求項５に記載の医薬。
【請求項７】 抗体がＹ２Ｂ８又は１３１Ｉ-Ｂ１(BEXXARＴＭ)を含んでなる請求項６に記載の医薬。
【請求項８】 抗体が静脈内投与される請求項１に記載の医薬。
【請求項９】 抗体が皮下投与される請求項１に記載の医薬。
【請求項１０】 ３７５ｍｇ／ｍ２未満の抗体用量が哺乳動物に投与される請求項１に記載の医薬。
【請求項１１】 用量が約２０ｍｇ／ｍ２〜約２５０ｍｇ／ｍ２の範囲である請求項１０に記載の医薬。
【請求項１２】 用量が約５０ｍｇ／ｍ２〜約２００ｍｇ／ｍ２の範囲である請求項１１に記載の医薬。
【請求項１３】 抗体は初期投与の後に二次投与されるものであり、二次投与における抗体のｍｇ／ｍ２用量が初期投与における抗体のｍｇ／ｍ２用量を越える請求項１に記載の医薬。
【請求項１４】 哺乳動物が異種抗原にさらされる前に抗体が哺乳動物に投与される請求項１に記載の医薬。
【請求項１５】 ＣＤ２０に結合する抗体の治療的有効量を含有してなる、哺乳動物における移植片対宿主又は宿主対移植片疾患を治療するための医薬。
【請求項１６】 哺乳動物の異種異種抗原に対する免疫応答をブロックするための医薬の製造における、ＣＤ２０を結合する抗体の使用。
【請求項１７】 医薬がさらに抗体にコンジュゲートされる細胞障害剤を含んでなる請求項１６に記載の使用。
【請求項１８】 哺乳動物の移植片対宿主又は宿主対移植片疾患を治療するための医薬の製造における、ＣＤ２０を結合する抗体の使用。
【請求項１９】 一以上の用量の抗体が静脈内投与される請求項８に記載の医薬。
【請求項２０】 一以上の用量の抗体が静脈内投与される請求項１５に記載の医薬。
【請求項２１】 一以上の用量の抗体が静脈内投与される請求項１６に記載の使用。
【請求項２２】 一以上の用量の抗体が静脈内投与される請求項１８に記載の使用。
【請求項２３】 実質的に実施例に記載される、請求項１ないし２２の何れか一に記載の方法又は使用。
JP2001509208A 1999-07-12 2000-07-10 Ｃｄ２０に結合するアンタゴニストを用いた異種抗原に対する免疫応答のブロッキング Withdrawn JP2003528805A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14440599P 1999-07-12 1999-07-12
US60/144,405 1999-07-16
PCT/US2000/018776 WO2001003734A1 (en) 1999-07-12 2000-07-10 Blocking immune response to a foreign antigen using an antagonist which binds to cd20

Publications (2)

Publication Number Publication Date
JP2003528805A JP2003528805A (ja) 2003-09-30
JP2003528805A5 true JP2003528805A5 (ja) 2007-08-30

Family

ID=22508442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001509208A Withdrawn JP2003528805A (ja) 1999-07-12 2000-07-10 Ｃｄ２０に結合するアンタゴニストを用いた異種抗原に対する免疫応答のブロッキング

Country Status (17)

Country Link
US (1) US20100003252A1 (ja)
EP (1) EP1216056A1 (ja)
JP (1) JP2003528805A (ja)
KR (2) KR20020027490A (ja)
CN (2) CN1373672A (ja)
AU (2) AU778863B2 (ja)
BR (1) BR0013201A (ja)
CA (1) CA2379274A1 (ja)
HK (1) HK1047702A1 (ja)
HU (1) HUP0202238A3 (ja)
IL (1) IL147547A0 (ja)
MX (1) MXPA02000419A (ja)
NO (1) NO20020128L (ja)
NZ (1) NZ516491A (ja)
PL (1) PL201086B1 (ja)
WO (1) WO2001003734A1 (ja)
ZA (1) ZA200200272B (ja)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
NZ556415A (en) * 2002-01-02 2009-02-28 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
PT1545613E (pt) 2002-07-31 2011-09-27 Seattle Genetics Inc Conjugados de auristatina e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infecciosa
CA2502552C (en) 2002-10-17 2019-02-12 Genmab A/S Human monoclonal antibodies against cd20
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
MXPA05010778A (es) 2003-04-09 2005-12-12 Genentech Inc Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa.
WO2005000901A2 (en) 2003-05-09 2005-01-06 Duke University Cd20-specific antibodies and methods of employing same
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
MXPA05013117A (es) 2003-06-05 2006-03-17 Genentech Inc Terapia de combinacion para trastornos de celulas-b.
JP2007504138A (ja) * 2003-08-29 2007-03-01 ジェネンテック・インコーポレーテッド 眼疾患の治療法
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
WO2005061542A2 (en) * 2003-12-19 2005-07-07 Genentech, Inc. Detection of cd20 in transplant rejection
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
AR049200A1 (es) 2004-06-04 2006-07-05 Genentech Inc Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20
WO2006020114A2 (en) 2004-08-04 2006-02-23 Applied Molecular Evolution, Inc. Variant fc regions
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2616386A1 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals Inc. Single dose use of cd20-specific binding molecules
RS54088B1 (en) 2005-07-25 2015-10-30 Emergent Products Development Seattle Llc B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
KR101643514B1 (ko) 2007-07-09 2016-07-27 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
CN101113459A (zh) * 2007-07-16 2008-01-30 东莞太力生物工程有限公司 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用
EP2233149B1 (en) 2007-10-16 2016-02-10 ZymoGenetics, Inc. Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
NZ588671A (en) 2008-04-11 2012-11-30 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
KR20180010324A (ko) 2009-08-11 2018-01-30 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
EP2499161B8 (en) * 2009-11-11 2017-10-25 Ganymed Pharmaceuticals GmbH Antibodies specific for claudin 6 (CLDN6)
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
EP3909602A1 (en) * 2014-04-25 2021-11-17 University of Florida Research Foundation, Inc. Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
RS60441B1 (sr) 2015-05-30 2020-07-31 Molecular Templates Inc De-imunizovane, strukture shiga toksin a podjedinice i ciljani ćelijski molekuli koji sadrže isti
PE20221007A1 (es) 2015-06-24 2022-06-15 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad disenada
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN114031689A (zh) 2015-10-02 2022-02-11 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
BR112018003984A2 (pt) 2015-12-09 2018-09-25 Hoffmann La Roche anticorpos

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
DK0669836T3 (da) * 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5417972A (en) * 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
WO1996031229A1 (en) * 1995-04-05 1996-10-10 Beth Israel Hospital Association Inhibiting rejection of a graft
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5877299A (en) * 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
DK81095A (da) * 1995-07-11 1997-01-12 Henrik S Thomsen Peroralt MR-kontraststof til lever og øvre tarmkanal
EP0938334A4 (en) * 1996-07-26 2004-12-15 Smithkline Beecham Corp IMPROVED METHOD FOR TREATING IMMUNE-MEDIATED SYSTEMIC DISEASES
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
GB2323386A (en) * 1997-03-20 1998-09-23 Procter & Gamble Effervescent detergent granules
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1999002567A2 (en) * 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
EP1946775A3 (en) * 1998-08-11 2008-08-06 Biogen Idec Inc. Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
AU2472400A (en) * 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
EP1035172A3 (en) * 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
AU782160B2 (en) * 1999-06-09 2005-07-07 Immunomedics Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
DE19930748C2 (de) * 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CN1981868A (zh) * 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
PL357939A1 (en) * 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
CN101130078A (zh) * 2000-04-25 2008-02-27 拜奥根Idec公司 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗
EP1296714B1 (en) * 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
JP4679035B2 (ja) * 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド 併用療法
EP2295468B1 (en) * 2002-02-14 2015-07-08 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
EP1944320A1 (en) * 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
MXPA05010778A (es) * 2003-04-09 2005-12-12 Genentech Inc Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa.
EP1682179A4 (en) * 2003-11-05 2008-09-03 Palingen Inc INCREASED CYTOTOXICITY OF CDIM BINDING ANTIBODY AGAINST B LYMPHOCYTES

Similar Documents

Publication Publication Date Title
JP2003528805A5 (ja)
Fennelly et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
Green et al. Whither radioimmunotherapy: to be or not to be?
US5538726A (en) Method and compositions for delivering cytotoxic agents to cancer
Dilda et al. Arsenical-based cancer drugs
Breitz et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin
JP2007515469A5 (ja)
JP2004512262A5 (ja)
EP4096671A1 (en) Combination therapy for treating abnormal cell growth
CA2422291A1 (en) Targeted alpha particle therapy using actinium-225 conjugates
Tuscano et al. Anti-CD22 ligand-blocking antibody HB22. 7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenografts
WO2022015736A9 (en) Combination therapy for treating abnormal cell growth
Kraeber-Bodéré et al. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen–expressing medullary thyroid cancer xenograft
Lindén et al. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma
Jäeger et al. Rituximab (anti‐CD20 monoclonal antibody) as consolidation of first‐line CHOP chemotherapy in patients with follicular lymphoma: a phase II study
Park et al. Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
KR101250127B1 (ko) Ｂ-세포 림프종의 치료를 위한 방사성표지된 안티-ｃｄ20항체와의 병용요법
Chen et al. Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug‐eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma
JP2005529152A5 (ja)
TW202144409A (zh) 抗vegf抗體和抗pd-1抗體組合用於預防或治療疾病的應用
Bagshawe et al. Preliminary therapeutic and localization studies with human chorionic gonadotrophin
CA2343120A1 (en) Use of an anthracycline derivative for the treatment of a liver tumor
Alvan et al. The pharmacokinetic profile of oxazepam
JPH0455172B2 (ja)